{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:51:02Z","timestamp":1781945462569,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bmcl.2025.130515","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:37:39Z","timestamp":1766594259000},"page":"130515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and synthesis of Tetrahydroindeno[4,5-c]chromen-4(3H)-one derivatives as antiproliferative agents for prostate Cancer cells"],"prefix":"10.1016","volume":"133","author":[{"given":"Hui-Yu","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Shuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Fang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzung-Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jih-Hwa","family":"Guh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmcl.2025.130515_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130515_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130515_bb0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/CCO.0b013e32835105b3","article-title":"The androgen\/androgen receptor axis in prostate cancer","volume":"24","author":"Bluemn","year":"2012","journal-title":"Curr Opin Oncol"},{"issue":"17","key":"10.1016\/j.bmcl.2025.130515_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175730","article-title":"Prostate Cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130515_bb0025","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.juro.2015.06.106","article-title":"Treating patients with metastatic castration resistant prostate Cancer: a comprehensive review of available therapies","volume":"194","author":"Crawford","year":"2015","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130515_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrurol.2013.274","article-title":"CYP17 inhibitors\u2014abiraterone, C17,20-lyase inhibitors and multi-targeting agents","volume":"11","author":"Yin","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130515_bb0035","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","article-title":"Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer","volume":"38","author":"Potter","year":"1995","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130515_bb0040","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1021\/jm040202w","article-title":"Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model","volume":"48","author":"Handratta","year":"2005","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.bmcl.2025.130515_bb0045","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.bmc.2011.08.066","article-title":"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer","volume":"19","author":"Kaku","year":"2011","journal-title":"Bioorg Med Chem"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130515_bb0050","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.bmcl.2014.04.024","article-title":"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors","volume":"24","author":"Rafferty","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130515_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4137\/CMRH.S14036","article-title":"Selective inhibition of steroidogenic enzymes by ketoconazole in rat ovary cells","volume":"8","author":"Gal","year":"2014","journal-title":"Clin Med Insights Reprod Health"},{"key":"10.1016\/j.bmcl.2025.130515_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2025.130515_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2018.02.004","article-title":"Discovery and development of ODM-204: a novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1","volume":"192","author":"Oksala","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.bmcl.2025.130515_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106148","article-title":"The design, structure-activity, and kinetic studies of 3-Benzyl-5-oxa-1,2,3,4-tetrahydro-2H-chromeno-(3,4-c)pyridin-8-yl sulfamates as steroid sulfatase inhibitors","volume":"129","author":"Chang","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2025.130515_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106581","article-title":"Design, structure-activity relationships, and enzyme kinetic studies of tricyclic and tetracyclic coumarin-based sulfamates as steroid sulfatase inhibitors","volume":"138","author":"Chiu","year":"2023","journal-title":"Bioorg Chem"},{"issue":"18","key":"10.1016\/j.bmcl.2025.130515_bb0080","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1021\/acs.joc.5b01802","article-title":"Insight into the mechanism of the Pechmann condensation reaction using NMR","volume":"80","author":"Tyndall","year":"2015","journal-title":"J Organomet Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2500424X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2500424X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:21:51Z","timestamp":1781943711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2500424X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":16,"alternative-id":["S0960894X2500424X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130515","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of Tetrahydroindeno[4,5-c]chromen-4(3H)-one derivatives as antiproliferative agents for prostate Cancer cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130515"}}